Looks like the Biomarkers being known by Jianda Yuan ...now at Merck ... became too much for Merck not to chase down and try and control PS Targeting IP
That last post, if read fully, shows why Precision For Medicine buys out Epiontis that was working on PS Targeting Biomarkers that Jianda Yuan had full access to data